ABSTRACT A role in portfolio management is ideal for individuals who enjoy tackling challenges that have both technical and business components. Portfolio management provides objective insights and analytics to support research and development decision making and planning. Successful practitioners usually have strong analytical abilities developed from a background in either science or business. Portfolio managers often advise key decision makers at both the team and senior management level and thus require robust oral, written, and interpersonal communication skills. Day-to-day tasks are rarely the same, and comfort with change and the unknown is essential. Here I will discuss my experience as a portfolio manager in a larger biopharmaceutical company and the skills from academic research I leveraged to make the transition.
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THE CHALLENGE OF FITTING THE PIECES INTO THE BIG PICTURE
Have you ever stepped back from your research to consider all the projects happening in parallel across a department and wonderHow do they fit together? Do the researchers on complementary projects efficiently collaborate? Are they overlapping? Are the resources going to the right places to advance the most significant science? Portfolio management is about seeing how pieces fit together to form a bigger picture in pursuit of a common goal. If you tend to think in big ideas and are drawn to shaping how the components of complex issues interact, then pivoting your career to portfolio management might be an attractive opportunity.
Within the drug development industry, many small biotechnology companies live and die pursuing the development of a single drug. Roughly one in 10 candidates achieves regulatory approval, which can take 8 years and cost more than a billion dollars (DiMasi et al., 2016) . The challenge lies in navigating the high level of uncertainty surrounding the science and seemingly stochastic nature of a drug's success. When a company scales up to have multiple programs running in parallel, the complexity of decision making, risk assessment, and resource allocation increases exponentially. This mix of parallel drug programs and their development over time are referred to as the portfolio and the pipeline, respectively. When developing multiple drugs, the challenge shifts to determining how to prioritize programs, manage risk, optimally concentrate programs within a disease area, and allocate limited resources, all with the goal of producing an impactful treatment for patients. Achieving this goal is ultimately the responsibility of senior management within a drug development company. Fortunately some companies provide the support of portfolio management professionals to advise on the strategic direction and decision making needed to usher a nascent drug from the bench to patients. These individuals may be found in strategy, product development, or portfolio management teams. Next I will describe the skills and techniques that portfolio management professionals at my company use to balance a portfolio of drug candidates, and how you too can transition from an academic to a business career.
A DAY IN THE LIFE OF A PORTFOLIO MANAGER
Each day brings unique challenges with new stakeholders from across the company. Portfolio management provides a varying set of services to its business partners (Figure 1 ). While details are project-specific, there are three main categories of services portfolio management provides: Strategic, Advisory, and Reporting.
Strategic
As a company matures its priorities change, the industry evolves, and it becomes necessary to alter its goals and approach to achieving them. This drive for change can come from company leaders or from grass-roots efforts. Irrespective of the source, it is essential that all parts of the organization agree and are moving in a shared direction. However, moving a large organization in unison is a this balance is essential to an efficient and productive flow of drug-candidates through the development pipeline. The portfolio management group is in a unique position-advising both individual drug program teams and senior management decision making. This provides an opportunity to align top-down vision and focus with grass-roots needs and innovation.
Reporting
From a company-wide perspective, portfolio management provides standard and ad hoc reports reflecting the current state of the portfolio and pipeline for internal communications. These reports can range from quarterly progress summaries to realtime online displays of a drug candidate program's status. Report details vary depending on the use case, but can include disease area, drug delivery platform, stage of development, mechanism of action, program value, program cost, and likelihood of success. Typical consumers of these reports are project teams, investor relations, finance, partnering, and senior management. We are often the first stop whenever someone is looking for a big-picture view of clinical development within the company.
CAREER TRAJECTORY How I got here
There is no defined path to obtain a position within portfolio management, but a common trait is dual proficiency in understanding scientific context and key business drivers of drug development. One third of our team have scientific backgrounds, a third have extensive business knowledge, and a third familiarity with both. An advanced scientific/medical degree and experience with business strategy such as management consulting or an MBA is valued, while a postdoc adds little.
My personal path began in the second half of my graduate studies when the repetition of experimental technique began to take a toll on my motivation. I found myself more engaged in discussing the implications of an experimental result rather than returning to the bench to refine the finding. Determining the impact of new discoveries on the human understanding of physiology and disease, and in turn patient health, became a strong driver of my interest in biology and new technologies. When I was more excited to hear the venture capitalist guest lecturer rather than a National Academy of Sciences member, I knew it was time for a change.
Without knowing how to leverage my scientific training in translational areas, I began to explore a number of opportunities. I engaged in a startup business competition, teamed up with a design firm to start a nonprofit educational organization, and began to build a network of like-minded scientists and professionals who were also following industry trends and analyses. After a brief start toward a management consulting career, I was introduced to a portfolio manager at Genentech and offered an internship position, which began after I completed my graduate work. The several years I spent working at biotechnology and pharmaceutical firms prior to graduate school facilitated my understanding of the many business partners touched by the portfolio group. The role morphed into a full-time position after 9 months-thus began my career in portfolio management.
challenging task with a multitude of stakeholder perspectives. Portfolio management, or a strategy group in some companies, may be tasked with developing options for the type of change and plans for accomplishing the new goals. Each strategic initiative is distinct, but a common approach starts with a situation assessment that includes surveying the internal and external landscape to determine the status of the issue at hand. This is followed by analysis and identification of critical drivers. Finally, alignment on potential solutions is sought with key stakeholders and recommendations presented to senior management. Previous strategic decisions our portfolio management team has participated in include optimizing the diseasearea mix within the portfolio, creating a framework for the role of backup programs in the portfolio, balancing the introduction of new programs versus the expansion of existing programs, and growing portfolio capacity.
Advisory
Within the portfolio, each drug candidate is supported by a team with representation from the major functions within research and development, including researchers, clinicians, clinical operations, finance, regulatory, and portfolio management. At the team level, portfolio management serves as a critical advisor and thought-partner; offering an outside perspective on how to stay competitive both within the internal portfolio and compared with external competitors. The specific tasks required in this advisory role are constantly shifting, depending on the type of drug candidate, its stage of development, and the disease area. Comfort with constant change and an appreciation for new challenges are essential to success in this aspect of the role. Some common tasks include risk identification/assessment, decision-analysis, scenario planning, and high-level valuations. The overarching goal of team support is to ensure that the team is presenting strong, data-driven options and recommendations when communicating with senior management.
Senior management often relies on portfolio management to provide an assessment of how a single program decision will impact the portfolio as a whole. This can provide context for program prioritization, resource allocation, and portfolio forecasting. Identifying nonobvious opportunity costs, systemic risks, and decision synergies is a key value-add of portfolio management. A critical service is to advise on properly balancing resources between new programs and progression or attrition of existing programs. Striking than a clever solution. If any of my key stakeholders feel the solution hasn't incorporated their concerns and perspective, it is unlikely to be effective. This may be the most challenging skill to develop from a PhD or academic background since it is often not emphasized in academia.
What to do after?
As roles in portfolio management are highly varied, career paths can be diverse. Between the exposure to multiple aspects of drug development and the broad applicability of the professional skills developed, it is not surprising that our company's portfolio management alumni can be found all over the industry. Examples include partnering, commercial, marketing, investment banking, and strategy groups. Notably, portfolio management alumni tend to be focused on business-centric careers and rarely return to a role directly involved in scientific or clinical pursuits.
FINDING YOUR PATH
A portfolio management position is a blend of the scientific and business domains, and a great way for a scientist to transition from academia to a business-orientated career. There are many ways to attain a portfolio management role, and many directions it can lead. Leveraging a strong professional network is a great way for PhDs to identify opportunities that are otherwise difficult to find. If you are genuinely interested in a role, talk to someone at a company you believe has potential to benefit from the skillsets described here. You never know where a position can be created, even if there is nothing advertised. A career path for a PhD is much like original research; there is no predefined process that guarantees results. Identifying a novel scientific finding or a professional opportunity requires a systematic approach and a dose of creativity. We each need to create our own unique path forward.
Your path will be unique, but there are several common skills that academic researchers already practice that will open opportunities related to portfolio management. The challenge is learning to apply these practices outside of experimental design.
Critical thinking
Be creative and objective in your assessment and analysis of an issue. The ability to identify key drivers and how they interrelate is a core skill used in strategic and advisory tasks. Creative new ways to analyze data or a scenario can lend insight that might be missed by an area expert. An unbiased perspective of the whole portfolio is essential to appropriately weighing program trade-offs, risks, and values against each other. A helpful technique is to envision what the issue looks like from different stakeholders' points of view. While the subject matter may be different, objectivity and creativity are fundamental to the scientific method, and scientists are seasoned practitioners who can leverage them in a business setting.
Flexible mindset
Stay agile and adaptable to change. There is constantly new information being generated that will require altering a plan or an underlying assumption. As academic researchers we typically generate a hypothesis and conceive elaborate experiments to determine its validity. On a drug-candidate team, or a strategic initiative, choices are often made with incomplete information. Comfort with ambiguity will help in prioritizing decision drivers.
Communication
Communication is critical. Having exceptional communication skills (both written and oral) is a necessary part of portfolio management due to the complexity of the topics and the diversity of business partners. Facilitation and teamwork are large aspects of the role. It is not unusual for team members to have significant disagreements on a topic that requires discussion and alignment before the project can progress. As an advisor, active listening is often more important REFERENCE DiMasi JA, Grabowski HG, Hansen RW (2016) . Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47, 20-33.
